Alnylam Pharmaceuticals, Inc. $ALNY is Casdin Capital LLC's 10th Largest Position

Key Points

• Casdin Capital cut its stake by 32.5%, selling 26,500 shares to hold 55,000 Alnylam shares (about 2.1% of its portfolio), valued at $25.08 million and making ALNY its 10th-largest position.
• Institutional ownership is very high (92.97%), with large moves this quarter including a new Norges Bank position ($662.8M) and major increases from Arrowstreet (up 698.8% to 1,355,609 shares), AQR and Orbis.
• Latest quarter missed expectations—Alnylam reported $1.25 EPS vs $1.43 expected and $1.10B revenue vs $1.16B expected, though revenue was up 84.9% YoY; analysts still show a "Moderate Buy" consensus with an average target of $477.96.

Casdin Capital LLC lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 32.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,000 shares of the biopharmaceutical company's stock after selling 26,500 shares during the quarter. Alnylam Pharmaceuticals makes up about 2.1% of Casdin Capital LLC's investment portfolio, making the stock its 10th largest holding. Casdin Capital LLC's holdings in Alnylam Pharmaceuticals were worth $25,080,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank bought a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at $662,837,000. Arrowstreet Capital Limited Partnership increased its position in shares of Alnylam Pharmaceuticals by 698.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company's stock worth $618,158,000 after purchasing an additional 1,185,909 shares during the last quarter. Holocene Advisors LP acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at about $194,616,000. AQR Capital Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 295.2% in the 3rd quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company's stock valued at $336,009,000 after purchasing an additional 555,759 shares in the last quarter. Finally, Orbis Allan Gray Ltd lifted its position in shares of Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock worth $691,771,000 after purchasing an additional 486,489 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Down 1.2%

NASDAQ:ALNY opened at $313.41 on Friday. The stock has a market cap of $41.56 billion, a price-to-earnings ratio of 183.28 and a beta of 0.36. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The business has a fifty day moving average of $344.35 and a 200-day moving average of $409.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing analysts' consensus estimates of $1.43 by ($0.18). The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. Alnylam Pharmaceuticals's revenue for the quarter was up 84.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.65) earnings per share. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ALNY. Royal Bank Of Canada decreased their price target on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an "outperform" rating for the company in a research note on Tuesday, January 20th. Wall Street Zen cut Alnylam Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 14th. Bank of America reaffirmed a "buy" rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Raymond James Financial reiterated an "outperform" rating and issued a $472.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. Finally, Oppenheimer initiated coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They issued an "outperform" rating and a $500.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $477.96.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Pushkal Garg sold 2,242 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $695,199.36. Following the completion of the transaction, the executive vice president directly owned 24,848 shares in the company, valued at $7,704,867.84. This trade represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jeffrey V. Poulton sold 2,780 shares of the firm's stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the transaction, the executive vice president owned 57,465 shares in the company, valued at $20,852,324.55. This represents a 4.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 53,923 shares of company stock worth $18,072,087 in the last 90 days. Corporate insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.